Pharmacological therapies for Angelman syndrome; [Pharmakologische Therapien bei Angelman-Syndrom]

被引：9
作者：
Tan W.-H. [1 ]
Bird L.M. [3 ,4 ]
机构：
[1] Harvard Medical School, Boston, MA
[2] Department of Pediatrics, University of California, San Diego, CA
[3] Division of Genetics/Dysmorphology, Rady Children’s Hospital San Diego, 3020 Children’s Way, # 5031, San Diego, 92123, CA
来源：
Wiener Medizinische Wochenschrift | 2017年 / 167卷 / 9-10期
关键词：
Angelman syndrome; Clinical trial; Mouse model; Therapeutic; Therapy;
D O I：
10.1007/s10354-015-0408-z
中图分类号：
学科分类号：
摘要：
Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by a loss of the maternally inherited UBE3A; the paternal UBE3A is silenced in neurons by a mechanism involving an antisense transcript (UBE3A-AS). We reviewed the published information on clinical trials that have been completed as well as the publicly available information on ongoing trials of therapies for AS. Attempts at hypermethylating the maternal locus through dietary compounds were ineffective. The results of a clinical trial using minocycline as a matrix metalloproteinase-9 inhibitor were inconclusive; another clinical trial is underway. Findings from a clinical trial using L-dopa to alter phosphorylation of calcium/calmodulin-dependent kinase II are awaited. Topoisomerase inhibitors and antisense oligonucleotides are being developed to directly inhibit UBE3A-AS. Other strategies targeting specific pathways are briefly discussed. We also reviewed the medications that are currently used to treat seizures and sleep disturbances, which are two of the more debilitating manifestations of AS. © 2015, Springer-Verlag Wien.
引用
收藏
页码：205 / 218
页数：13
相关论文
共 117 条
[31]  
Evers M.M., Toonen L.J., van Roon-Mom WM, (2015)
[32]  
Meng L., Ward A.J., Chun S., Et al., Towards a therapy for Angelman syndrome by targeting a long non-coding RNA, Nature, 518, pp. 409-412, (2015)
[33]  
Daily J.L., Nash K., Jinwal U., Et al., Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome, PLoS One, 6, (2011)
[34]  
Lisman J., Schulman H., Cline H., The molecular basis of CaMKII function in synaptic and behavioural memory, Nat Rev Neurosci, 3, pp. 175-190, (2002)
[35]  
Blitzer R.D., Iyengar R., Landau E.M., Postsynaptic signaling networks: cellular cogwheels underlying long-term plasticity, Biol Psychiatry, 57, pp. 113-119, (2005)
[36]  
Giese K.P., Fedorov N.B., Filipkowski R.K., Et al., Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning, Science, 279, pp. 870-873, (1998)
[37]  
Elgersma Y., Fedorov N.B., Ikonen S., Et al., Inhibitory autophosphorylation of CaMKII controls PSD association, plasticity, and learning, Neuron, 36, pp. 493-505, (2002)
[38]  
Weeber E.J., Jiang Y.H., Elgersma Y., Et al., Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome, J Neurosci, 23, pp. 2634-2644, (2003)
[39]  
van Woerden G.M., Harris K.D., Hojjati M.R., Et al., Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation, Nat Neurosci, 10, pp. 280-282, (2007)
[40]  
Brown A.M., Deutch A.Y., Colbran R.J., Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism, Eur J Neurosci, 22, pp. 247-256, (2005)
12345678910